Pharmacy · Independent exam preparation
PTCB PTCE Preparation: Medication Decisions, Federal Rules, and Processing Skills Study Guide
Practise medication risk recognition, federal dispensing rules, error prevention, and prescription calculations through 60 focused PTCE concepts and original drills.
By CertMedbry · Updated 30 October 2026
Recognise duplicate therapy, distinguish contraindications from precautions, calculate quantities accurately, and identify dispensing problems that require pharmacist intervention. This selective guide develops 60 practical concepts across the four PTCE domains, with worked applications, common pitfalls, original questions, and recall cards. Use the official PTCE Content Outline for the full examination scope; the examples here develop selected decisions rather than exhaust every medication, regulation, or calculation.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and credential does this guide cover?
It covers PTCB's Pharmacy Technician Certification Examination, or PTCE, for the Certified Pharmacy Technician, or CPhT, credential. CPhT names the credential; PTCE names the examination. Advanced CPhT and other specialist credentials have separate requirements and are outside this guide.
How many questions are on the PTCE?
PTCB specifies 90 multiple-choice questions: 80 scored and 10 unscored. The unscored questions are placed throughout the examination and are not identified, so candidates should give every question full consideration.
How much time is available?
Examination time is 110 minutes. PTCB describes a two-hour appointment consisting of a five-minute tutorial, the examination, and a five-minute post-examination survey.
How is the examination delivered, and is it adaptive?
PTCB describes a computer-based, multiple-choice examination taken at a Pearson test center under a live proctor. The cited examination description does not establish an adaptive testing design. The questions in this guide are independent four-option learning drills.
Which blueprint applies to this guide?
The guide uses PTCE Content Outline v1.4, dated August 2024 and effective January 6, 2026. The document date and effective date serve different purposes. The four domains and weights are Medications 35%; Federal Requirements 18.75%; Patient Safety and Quality Assurance 23.75%; Order Entry and Processing 22.50%.
How does the Knowledge Reference differ from the examination outline?
The 2026 CPhT Knowledge Reference includes PTCE knowledge areas alongside additional required and recommended technician knowledge. Its broader coverage does not make every listed statement an examination topic. The official content outline defines the full tested scope; these 60 concepts selectively develop that scope.
2026 PTCB Certified Pharmacy Technician Knowledge Reference · PTCE Content Outline — Effective January 6, 2026
Do different eligibility pathways require different examinations?
PTCB identifies completion of a recognised education or training program, or equivalent work experience, as routes toward CPhT eligibility. These routes lead to the PTCE rather than separate examinations in this guide. Candidates must also meet PTCB's other eligibility and certification requirements.
Which jurisdiction governs the legal examples?
Federal-law examples concern United States federal requirements. State boards define technician scope, and applicable state rules can add restrictions. The DEA Pharmacist's Manual cited for selected controlled-substance principles is its 2022 edition; it should not be treated as a complete account of every later regulatory change.
PTCB Certified Pharmacy Technician (CPhT) · DEA Pharmacist's Manual, 2022 Edition
How are the learning materials distributed across domains?
The 60 concepts comprise 21 Medications, 11 Federal Requirements, 14 Patient Safety and Quality Assurance, and 14 Order Entry and Processing concepts. Both the 20 questions and 20 flashcards use a 7/4/5/4 allocation. These rounded allocations approximate the official weights and do not reproduce an official examination form.
This guide follows the Pharmacy Technician Certification Board's Pharmacy Technician Certification Examination, the qualifying examination for PTCB's Certified Pharmacy Technician credential. It addresses technician knowledge and processing responsibilities. These independent educational materials are not official PTCB examination items or a prediction of examination performance.
Outline used: PTCE Content Outline v1.4, dated August 2024, effective January 6, 2026; verified for October 11, 2026. The workbook label Certified Pharmacy Technician (CPhT) names the credential; PTCB identifies the PTCE as its qualifying examination. The assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Medications35%
1.What connects Lipitor, atorvastatin, and the statin class?
Lipitor is a brand name for atorvastatin, an HMG-CoA reductase inhibitor commonly called a statin. Brand, generic, and class describe different levels of medication identity. Recognising the same active ingredient under different names helps prevent duplicate entries and incorrect product selection. For processing, connect the name to the ordered strength and dosage form; knowing the class alone does not establish that two products are the same medication.
Apply it
A prescription requests atorvastatin tablets, while the patient calls the medication Lipitor. Link both names to the same active ingredient, then compare the prescribed strength and formulation with the stock product before staging it for verification.
Common pitfall: A shared therapeutic purpose does not establish ingredient identity. Another cholesterol medicine cannot be selected simply because it treats the same condition.
2.How can brand and generic entries conceal duplicate therapy?
Duplicate therapy can arise when a medication profile lists one active ingredient under both its brand and generic names. The important comparison is what the patient actually takes, including strengths, schedules, and whether one order replaced another. Two entries may represent a documented switch rather than simultaneous therapy. Identify the overlapping ingredient and unresolved directions so the pharmacist can distinguish an administrative duplicate from unintended additional exposure.
Apply it
A patient reports taking a tablet from a Lipitor bottle each morning and a tablet from an atorvastatin bottle each evening. Record both strengths and actual use, then flag the ingredient overlap for pharmacist assessment.
Common pitfall: Do not automatically delete one entry or assume the second bottle is harmless. A replacement prescription and concurrent duplicate use require different responses.
DailyMed: Lipitor prescribing information · PTCE Content Outline — Effective January 6, 2026
3.When do muscle symptoms during atorvastatin treatment matter?
Atorvastatin can cause myopathy and rhabdomyolysis, so unexplained muscle pain, tenderness, or weakness is a meaningful safety signal. Symptoms accompanied by malaise or fever deserve particular attention. The technician's useful contribution is to recognise the medication association and communicate onset, severity, and recent changes. A symptom report does not establish the diagnosis, but it should not be dismissed as an expected consequence of cholesterol treatment.
Apply it
A patient collecting atorvastatin reports new widespread weakness after a recent dosage increase. Pause the routine pickup conversation and promptly communicate the symptoms and timing to the pharmacist for assessment and appropriate action.
Common pitfall: Reassuring the patient that all muscle pain is minor can delay assessment. Conversely, attributing every ache to a statin exceeds the available evidence.
4.Why does combining naproxen with another NSAID raise concern?
Naproxen is a nonsteroidal anti-inflammatory drug. Adding another NSAID can increase gastrointestinal toxicity while providing little or no additional efficacy. Different brand names, strengths, or purchase locations do not remove this class overlap. Review prescription and nonprescription products together, including combination remedies. The discriminating clue is concurrent exposure to the same risk-producing class, rather than merely the presence of two medicines used for pain.
Apply it
A patient taking prescribed naproxen asks whether an OTC ibuprofen product can be added for breakthrough pain. Identify the NSAID duplication and present the complete medication information to the pharmacist before a recommendation is made.
Common pitfall: An OTC product is not automatically safe to combine with a prescription. Do not treat all pain relievers as interchangeable members of one class.
5.Which gastrointestinal symptoms during naproxen use require urgent attention?
NSAIDs such as naproxen can cause gastrointestinal bleeding, ulceration, and perforation. Black, tarry stools or vomiting blood are important warning signs because they suggest bleeding rather than ordinary stomach discomfort. Serious gastrointestinal events can occur without preceding warning symptoms. Recognise the pattern, alert the pharmacist immediately, and support urgent assessment through the pharmacy's emergency process instead of treating the report as a routine request for an upset-stomach remedy.
Apply it
A patient taking naproxen mentions black, sticky stools and lightheadedness while requesting an antacid. Immediately communicate the possible bleeding symptoms to the pharmacist and support urgent medical evaluation rather than continuing a routine OTC transaction.
Common pitfall: Taking naproxen with food does not eliminate serious gastrointestinal risk. Symptom relief from an antacid would not establish that bleeding has been excluded.
6.Why is sildenafil contraindicated with nitrates?
Sildenafil potentiates the blood-pressure-lowering effects of nitrates through the nitric oxide and cyclic GMP pathway. Combined exposure can produce dangerous hypotension. The contraindication includes organic nitrates or nitrites used regularly or intermittently, so an as-needed nitrate remains relevant even when rarely used. Identify the combination before dispensing and communicate it for pharmacist resolution. A technician should not invent a spacing interval to make the combination acceptable.
Apply it
A sildenafil prescription arrives for a patient whose profile includes as-needed nitroglycerin. The patient says the nitrate has not been needed recently. Flag the contraindicated combination because intermittent nitrate use still matters to the safety assessment.
Common pitfall: Separating the medicines by a convenient number of hours is not an independently justified solution. Rare nitrate use does not remove the contraindication.
DailyMed: Sildenafil citrate tablets prescribing information
7.How does sildenafil with an alpha-blocker differ from sildenafil with a nitrate?
Sildenafil and alpha-blockers can have additive blood-pressure-lowering effects, creating a risk of symptomatic hypotension. The label describes precautions involving stability on alpha-blocker therapy and careful initiation, rather than the nitrate combination's absolute contraindication. This distinction matters when interpreting alerts: a precaution can require clinical conditions and monitoring without meaning that every combination is forbidden. Collect dizziness, fainting, recent initiation, and dosage-change information for the pharmacist's assessment.
Apply it
A patient receiving an alpha-blocker presents a new sildenafil prescription and reports recent dizziness when standing. Record the symptoms and treatment timing, then flag the additive hypotension risk before the prescription proceeds to dispensing.
Common pitfall: Calling every interaction a contraindication loses useful distinctions. Ignoring a precaution because the combination is sometimes permitted is equally unsafe for this patient.
DailyMed: Sildenafil citrate tablets prescribing information
8.What therapeutic role does inhaled albuterol serve?
Albuterol is a beta-adrenergic agonist used to treat or prevent bronchospasm. Its bronchodilator action helps distinguish it from medicines whose main role is controlling airway inflammation. The product's indication and route must both match the prescription. Repeated requests for more medication or reports that the usual amount no longer works are clinically relevant clues; they should prompt pharmacist assessment rather than an assumption that increasing use is routine.
Apply it
A patient requests an early albuterol refill because the inhaler is being used much more often and relief lasts less time. Gather actual use and symptom details, then alert the pharmacist to possible deterioration in respiratory control.
Common pitfall: Bronchodilation does not establish adequate control of the underlying disease. Do not interpret frequent rescue use as proof that the current treatment plan is sufficient.
9.How do tremor and nervousness after albuterol differ from allergy clues?
Tremor and nervousness are recognised adverse effects of albuterol and do not, by themselves, establish an immune-mediated allergy. The distinction depends on the reported symptoms, timing, severity, and accompanying features. Record the patient's own description rather than converting every unwanted effect into an allergy label. The pharmacist still needs to assess troublesome symptoms, particularly when use has increased, because a recognised adverse effect is not automatically harmless.
Apply it
A patient describes shaky hands after albuterol but denies rash, swelling, or breathing deterioration. Document the specific symptoms and frequency of use for pharmacist assessment instead of entering an unexplained albuterol allergy into the profile.
Common pitfall: An adverse effect can require intervention without being an allergy. Conversely, the absence of a rash does not exclude every serious drug reaction.
10.When can albuterol unexpectedly worsen breathing?
Inhaled albuterol can produce paradoxical bronchospasm, a potentially life-threatening worsening of airway narrowing after administration. The crucial cue is breathing that becomes worse immediately after using a medicine intended to relieve bronchospasm, particularly with a new canister. This pattern requires urgent clinical assessment rather than routine reassurance about mild stimulant effects. The label calls for immediate discontinuation and alternative therapy when paradoxical bronchospasm occurs.
Apply it
A patient reports that the first use of a new albuterol canister immediately intensified wheezing and chest tightness. Alert the pharmacist at once and activate the appropriate urgent response for worsening respiratory symptoms.
Common pitfall: Automatically recommending additional inhalations could worsen exposure to the suspected trigger. Do not group immediate breathing deterioration with ordinary nervousness or hand tremor.
11.Why must the cited metformin extended-release tablets remain intact?
The cited metformin extended-release tablets must be swallowed whole and must not be crushed, cut, or chewed. Manipulating a modified-release product can defeat its intended delivery characteristics. An oral route does not mean that every tablet can be altered for swallowing difficulty. Identify the exact formulation before suggesting administration changes, and bring the swallowing problem to the pharmacist so an appropriate formulation or treatment plan can be considered.
Apply it
A caregiver asks whether a metformin extended-release tablet can be crushed into applesauce. Explain that this product's instructions prohibit crushing and promptly involve the pharmacist to address the patient's difficulty swallowing the intact tablet.
Common pitfall: Advice appropriate for one immediate-release tablet cannot be transferred to an extended-release product. A smaller physical piece does not preserve the labelled release properties.
12.Which renal thresholds distinguish metformin contraindication from reassessment?
The cited metformin extended-release label contraindicates use when eGFR is below 30 mL/min/1.73 m². Initiation is not recommended between 30 and 45, while a decline below 45 during established treatment calls for assessment of continuing benefit and risk. Renal impairment can increase metformin accumulation and lactic acidosis risk. Distinguish starting therapy from continuing existing therapy; the same intermediate renal result does not describe identical decisions in both situations.
Apply it
A new metformin extended-release prescription is presented with a recent eGFR of 38 mL/min/1.73 m². Identify that initiation is not recommended in this range and route the prescription for pharmacist assessment before it advances.
Common pitfall: Do not describe every eGFR below 45 as the same absolute contraindication. The below-30 threshold and the initiation caution are different label criteria.
13.How does breakfast timing affect levothyroxine administration?
The cited levothyroxine tablet label directs a single daily dose on an empty stomach, one-half to one hour before breakfast. Food can affect absorption, so administration timing helps maintain consistent exposure. A patient taking the same tablet strength under a different food routine may receive a different effective exposure. Recognise changes in administration habits as useful information for pharmacist assessment before assuming that an unexpected response requires a different prescribed strength.
Apply it
A patient who previously took levothyroxine before breakfast now takes it with a large morning meal. Document the changed routine and communicate it to the pharmacist when the patient reports concerns about treatment effectiveness.
Common pitfall: The printed strength alone does not determine exposure. Do not assume that taking the medicine sometime during the morning satisfies its specific administration instructions.
14.Why should iron be separated from levothyroxine?
Iron preparations can bind levothyroxine and reduce its gastrointestinal absorption. The cited tablet label directs separation by at least four hours from agents such as ferrous sulfate. This is an absorption interaction, so simply using different beverages does not resolve simultaneous administration. Include supplements when gathering a medication history because an apparently unrelated mineral product can change exposure to a prescription medicine without changing the prescribed tablet strength.
Apply it
A patient takes levothyroxine and ferrous sulfate together before breakfast. Identify the absorption interaction and bring the schedule to the pharmacist so the patient can receive a practical plan maintaining the required separation.
Common pitfall: Waiting only until breakfast is finished may still provide insufficient separation. Vitamins and minerals belong in interaction screening even when purchased without a prescription.
15.What temperature, light, and moisture conditions apply to the cited levothyroxine tablets?
The cited levothyroxine label specifies storage at 25°C (77°F), with excursions permitted to 15–30°C (59–86°F), and protection from light and moisture. Distinguish the storage target from the permitted excursion range: 25°C is the stated storage temperature, while a temporary departure within 15–30°C is permitted. The excursion range does not make every temperature within it an intended permanent storage target. Protection from light and moisture remains necessary even when the temperature is acceptable.
Apply it
A storage area normally maintained at 25°C briefly reaches 28°C. That temperature is within the label's permitted excursion range. A recorded temperature of 32°C exceeds that range: separate affected stock from usable inventory, document the temperature and exposure duration, and obtain a product-specific stability assessment before release. An open container beside a steamy shower also fails moisture protection, even at 25°C.
Common pitfall: An unexpired date does not establish suitability after improper storage. Returning exposed tablets to 25°C does not demonstrate that their quality was preserved. Likewise, refrigeration is not an automatic remedy; the cited label does not specify refrigerated storage.
16.Which allergy history is especially important before amoxicillin dispensing?
Amoxicillin is a penicillin-class antibacterial. The cited label contraindicates it in patients with a history of serious hypersensitivity reactions to amoxicillin or other beta-lactam antibacterials, including anaphylaxis or Stevens-Johnson syndrome. The actual reaction matters more than a vague allergy entry. Capture the implicated drug and described reaction so the pharmacist can evaluate the order accurately, without independently reclassifying a serious historical reaction as an ordinary side effect.
Apply it
A new amoxicillin order appears for a patient who reports throat swelling and emergency treatment after a previous penicillin dose. Document those details and stop routine processing for pharmacist assessment of the serious hypersensitivity history.
Common pitfall: A remote reaction is not automatically irrelevant. Equally, isolated nausea should not be silently converted into a history of anaphylaxis without supporting information.
17.Why must an oral suspension be shaken before measurement?
A suspension contains dispersed particles that can settle during storage. Shaking redistributes them so a measured volume more closely represents the labelled concentration. The cited amoxicillin suspension specifically requires shaking well before use. Correct syringe technique alone cannot compensate for sampling a poorly mixed preparation. Treat mixing and measurement as separate steps: first restore a uniform dispersion, then measure the prescribed volume with an appropriate calibrated device.
Apply it
A caregiver measures amoxicillin from the clear-looking top layer of a bottle that has stood overnight. Explain the need to shake the suspension before measuring and arrange pharmacist guidance about any potentially inaccurate previous doses.
Common pitfall: The correct number of millilitres does not ensure the correct drug amount when the suspension is uneven. Do not assume every liquid medicine is a solution.
18.How does reconstitution water differ from the final suspension volume?
The water added to a dry powder is not necessarily equal to the final suspension volume because the powder contributes volume. Use the manufacturer's directions for the exact strength and bottle size. For the cited amoxicillin product, a 100 mL bottle of 250 mg/5 mL suspension requires 73 mL of water. Adding 100 mL would dilute the preparation beyond its intended concentration and make subsequent volume-based dosing inaccurate.
Apply it
You prepare the cited 100 mL amoxicillin bottle labelled 250 mg/5 mL. Use its specified 73 mL of water and mixing sequence, then verify that the resulting product and label correspond to the ordered concentration.
Common pitfall: Do not substitute final bottle volume for water volume. A mixing instruction for another strength, manufacturer, or bottle size may produce a different concentration.
19.When must the cited reconstituted amoxicillin suspension be discarded?
The cited amoxicillin suspension must be discarded after 14 days following reconstitution. Refrigeration is preferable for this product but is not required. Reconstitution starts a product-specific usable period that differs from the manufacturer's expiration for unopened dry powder. Record preparation timing and communicate the discard instruction clearly. Neither remaining liquid nor acceptable appearance establishes that the suspension remains suitable beyond its labelled post-reconstitution period.
Apply it
A caregiver finds leftover amoxicillin suspension prepared three weeks earlier and wants to restart it for new symptoms. Identify that its 14-day post-reconstitution period has passed and refer the new illness question to the pharmacist.
Common pitfall: The original package expiration does not override the shorter reconstituted period. Do not apply this product's refrigeration or discard instructions to every antibiotic suspension.
20.Why must an inhaler canister match its intended actuator?
The cited albuterol aerosol is a drug-device system, and its label directs users not to interchange its canister and actuator with those from other inhalers. The actuator contributes to reliable medication delivery; physical fit alone does not establish compatibility. Check the complete product rather than treating the plastic mouthpiece as a generic accessory. Product-specific priming and cleaning instructions also matter because medication buildup or incorrect preparation can interfere with delivery.
Apply it
A patient has placed an albuterol canister into a different inhaler's plastic actuator because it fits. Identify the mismatch and involve the pharmacist to restore a compatible device and review the product's preparation and cleaning instructions.
Common pitfall: A canister that fits mechanically is not necessarily validated for that actuator. Do not generalise one inhaler's priming procedure to every aerosol product.
21.When does iodinated contrast require special handling of metformin therapy?
The cited metformin extended-release label describes temporary discontinuation for specified iodinated contrast procedures, including patients with eGFR from 30 to 60 mL/min/1.73 m² and those receiving intra-arterial contrast. Renal function is reassessed 48 hours afterward, and restarting requires stable renal function. The key distinction is a procedure-related safety plan, not a universal instruction to stop metformin before every imaging study or automatically restart it when time passes.
Apply it
A patient taking metformin extended-release, with eGFR 48 mL/min/1.73 m², reports scheduled iodinated contrast imaging. Flag the procedure and renal result so the pharmacist can coordinate the labelled interruption and renal reassessment plan.
Common pitfall: Elapsed time alone does not establish safe restarting. Do not assume that an imaging appointment necessarily uses iodinated contrast or satisfies the same risk criteria.
Federal Requirements18.75%
22.How do the five federal controlled-substance schedules differ, and how do schedules affect prescription processing?
A schedule is a legal classification based on accepted medical use, relative abuse potential, and dependence risk; a therapeutic class describes clinical use or pharmacology. Schedule I substances, such as heroin, have high abuse potential, no currently accepted U.S. medical use, and lack accepted safety under medical supervision. Schedules II–V have accepted medical uses. Schedule II includes oxycodone: abuse potential is high, and abuse may cause severe physical or psychological dependence. Schedule III includes buprenorphine: abuse potential is lower than in Schedules I–II, with moderate or low physical dependence or high psychological dependence possible. Schedule IV includes alprazolam: abuse potential is lower than in Schedule III, with limited dependence relative to Schedule III. Schedule V has lower abuse potential and limited dependence relative to Schedule IV; examples include qualifying cough preparations containing no more than 200 mg codeine per 100 mL.
Apply it
An oxycodone prescription cannot be refilled because oxycodone is Schedule II; further dispensing requires an appropriate new prescription rather than a refill authorization. Buprenorphine is Schedule III and alprazolam is Schedule IV. Under federal rules, their prescriptions may have up to five authorized refills within six months after issuance. Both the number of refills remaining and the prescription's age must permit processing; state requirements may impose additional restrictions.
Common pitfall: Do not infer schedules from indication or dosage alone. Oxycodone and buprenorphine are both opioids but occupy different schedules. Codeine-containing products can have different schedules depending on formulation and concentration. These examples are selective; the official PTCE Content Outline defines the full examination scope.
DEA Pharmacist's Manual, 2022 Edition · Diversion Control Division | Controlled Substance Schedules · PTCE Content Outline — Effective January 6, 2026
23.Why can a Schedule II prescription not be refilled?
Federal requirements prohibit refilling a Schedule II prescription. A prescriber's written refill instruction does not create valid refill authority for this schedule. Distinguish a refill from a separate prescription or a legally permitted partial dispensing of an existing prescription; those are different transactions with different conditions. When a refill request arrives, recognise the schedule-based restriction and route the request for the appropriate new-prescription process rather than overriding the restriction.
Apply it
A Schedule II prescription was completely dispensed last month, but the patient requests another fill from the same prescription number. Identify that this would be a refill and initiate pharmacist review of the need for a new prescription.
Common pitfall: An insurance claim accepting the transaction does not establish legal authority. Do not confuse an authorised partial-fill balance with a refill after complete dispensing.
24.How do the federal refill limits for Schedules III–IV operate?
An authorised Schedule III or IV prescription may be refilled up to five times within six months after its issue date. Both limits apply: reaching five refills or passing six months requires a new prescription, whichever occurs first. The initial dispensing is not counted as a refill. Transferring an existing prescription does not create a new issue date or restore exhausted refill authority; the remaining lawful authority must still be established.
Apply it
A Schedule IV prescription has had its initial dispensing and five authorised refills within four months. A sixth refill is requested. Identify the exhausted refill count even though the six-month period has not yet ended.
Common pitfall: Counting the original fill as a refill understates available authority. Counting only time ignores the separate maximum of five refills for these schedules.
25.Which ordering record applies to ordinary Schedule II stock acquisition?
DEA Form 222 or its authorised electronic equivalent is used for ordinary Schedule II controlled-substance ordering. This concerns movement of stock between authorised parties, not the patient's prescription authorisation. Receiving documentation should correspond to what actually arrived, including container quantities and receipt date. Distinguishing stock acquisition from patient dispensing prevents misuse of forms and supports accountability when the shipped quantity differs from the quantity ordered.
Apply it
A pharmacy orders six commercial containers of a Schedule II medication but receives four. Use the appropriate controlled-substance ordering process and record the actual containers received rather than marking the full order as delivered.
Common pitfall: A patient prescription is not a substitute for a stock-ordering record. An invoice total should not be copied as the received quantity without checking the shipment.
26.How should a controlled-stock discrepancy be investigated, and when must the registrant report theft or significant loss?
An unexplained discrepancy requires prompt investigation; it does not automatically establish theft or significant loss. Recount stock, compare receipts and dispensing records, preserve original information, secure affected inventory, and immediately notify the responsible pharmacist. The DEA registrant is responsible for determining significance and reporting. Relevant factors include the quantity missing relative to the business, the specific substance, access by particular individuals, repeated loss patterns, diversion potential, and local diversion trends. There is no universal tablet-count threshold. Under 21 CFR 1301.76(b), the registrant must notify the local DEA Field Division Office in writing within one business day after discovering theft or significant loss. A complete and accurate DEA Form 106 must also be submitted electronically through DEA's secure application within 45 calendar days after discovery. Theft is reportable regardless of whether the quantity would independently constitute a significant loss.
Apply it
A technician finds an oxycodone shortage. A documented recount and review of receipts and dispensing records do not explain it, so the technician promptly escalates the findings without erasing the discrepancy. Repeated small shortages can support a significant-loss determination even when each individual shortage is small. If the registrant discovers theft or determines that a significant loss occurred, the written one-business-day notification and electronic 45-calendar-day Form 106 requirements apply. The later form deadline does not extend the initial notification deadline.
Common pitfall: Do not silently adjust records to make stock balance, assume every counting error requires Form 106, or wait for the final investigation report before making the required initial notification after discovery of theft or significant loss. A designated employee may prepare reports, but responsibility remains with the registrant.
2023-13085.pdf · DEA Pharmacist's Manual, 2022 Edition · PTCE Content Outline — Effective January 6, 2026
27.How should a pharmacy calculate federal pseudoephedrine limits and distinguish fixed-location sales from other sales channels?
Federal pseudoephedrine quantity limits use pseudoephedrine base content. A marketed salt strength, such as pseudoephedrine hydrochloride, must not automatically be treated as the same mass of base. Use the product's established base equivalent before comparing quantities with legal limits. For fixed-location, in-person pharmacy sales, the federal daily sales limit is 3.6 g base per purchaser, regardless of the number of transactions, and the purchaser's overall retail purchase limit is 9 g base during a 30-day period. Additional restrictions apply: mail-order sellers and mobile retail vendors are limited to 7.5 g base per customer during a 30-day period. Within the purchaser's overall 9 g base allowance, no more than 7.5 g base may be imported through private or commercial carrier or the Postal Service. Restricted access, identification, and applicable logbook requirements must also be satisfied.
Apply it
For an arithmetic example, each hypothetical tablet contributes exactly 30 mg pseudoephedrine base; this is explicitly a base-equivalent amount. Two packages of 48 tablets contain 2 × 48 × 30 = 2,880 mg, or 2.88 g base. With no earlier purchases today, that amount is below the 3.6 g base daily limit, but the separate 30-day total still needs checking. For example, a customer with 7.8 g base already purchased during the relevant period would exceed the 9 g base limit even by buying one such 48-tablet package: 7.8 + 1.44 = 9.24 g base.
Common pitfall: The cited marketed tablet contains 30 mg pseudoephedrine hydrochloride, which is the salt mass rather than 30 mg base. Do not apply the hypothetical tablet's base amount to that product. Passing a quantity check also does not satisfy identification, access-control, logbook, or additional state requirements.
Diversion Control Division | CMEA General Information · FDA: Combat Methamphetamine Epidemic Act · Pseudoephedrine Hydrochloride 30 mg Drug Facts
28.How are hazardous and non-hazardous pharmaceutical wastes classified and routed for disposal?
A discarded pharmaceutical is hazardous under federal RCRA rules when it meets an applicable hazardous-waste listing or exhibits ignitability, corrosivity, reactivity, or toxicity. Prescription status, expiration, and therapeutic class alone do not determine that classification. The P-list covers acutely hazardous discarded commercial chemical products; for an unused formulation, the listed chemical must be its sole active ingredient for that listing to apply. Applicable exclusions also matter. For example, discarded FDA-approved OTC nicotine patches, gums, and lozenges are exempt from the P075 nicotine listing where the state has adopted that exemption. A waste that meets no listing or characteristic is non-hazardous under federal RCRA rules, although other disposal requirements may apply. Pharmacy-owned inventory waste requires the applicable facility waste process. Household medicine disposal and household take-back collections are separate streams and do not authorise disposal of pharmacy inventory through consumer methods.
Apply it
A pharmacy discards expired FDA-approved OTC nicotine gum in a state that has adopted the P075 exemption. If no other hazardous listing or characteristic applies, classify it as federally non-hazardous pharmaceutical waste and use the facility's corresponding disposal stream. Separately, an unused cyclophosphamide commercial product meets the U058 listing. If it is non-creditable waste at a facility operating under subpart P, segregate it for the hazardous-waste pharmaceutical disposal pathway rather than a household take-back bin, ordinary trash, or a drain. Potentially creditable prescription hazardous waste follows the applicable reverse-distribution process instead of being assumed eligible solely because it is expired.
Common pitfall: Non-hazardous does not mean suitable for dispensing, and hazardous does not mean controlled under DEA schedules. Do not classify every nicotine product as exempt: the exemption specifically covers FDA-approved OTC patches, gums, and lozenges and must be effective in the state. Hazardous waste pharmaceuticals from healthcare facilities must not be sewered, including at very small quantity generators.
Frequent Questions about the Management Standards for Hazardous Waste Pharmaceuticals and Amendment to the P075 Listing for Nicotine Final Rule | US EPA · PTCE Content Outline — Effective January 6, 2026
29.When do REMS requirements prevent routine dispensing?
A Risk Evaluation and Mitigation Strategy addresses a medication-specific serious safety concern. Some programs require activities before a medicine may be prescribed, dispensed, or received, such as certification, enrolment, or documented safe-use conditions. Requirements differ by product and program. Confirm the relevant conditions for the medication and transaction rather than treating REMS as a universal checklist. A valid prescription does not by itself satisfy an additional required dispensing authorisation.
Apply it
A prescription is otherwise complete, but its applicable REMS requires a dispensing authorisation that has not been documented. Hold release while the pharmacist resolves the missing program requirement, even if the insurance claim has already been paid.
Common pitfall: Do not assume that every REMS requires the same testing or enrolment. Insurance approval and prescription validity do not replace medication-specific safe-use requirements.
30.What does a Class I recall communicate?
A Class I recall indicates a reasonable probability that use of or exposure to a violative product will cause serious adverse health consequences or death. The classification describes risk severity, while the recall notice identifies affected products and the required response. Match product and lot information, remove affected stock from dispensing, and follow the notice's instructions. Do not wait for a patient injury before acting on a qualifying recall.
Apply it
A Class I notice lists one lot of a stocked medication. Compare the notice with each container's identifiers, segregate matching units from usable stock, and help the pharmacist trace any affected dispensing according to the recall instructions.
Common pitfall: A recall may be limited to specified lots rather than every product with that drug name. Class I severity does not replace careful identifier matching.
FDA: Recalls Background and Definitions · PTCE Content Outline — Effective January 6, 2026
31.Why must suspect DSCSA products be quarantined?
DSCSA safeguards help prevent counterfeit or other illegitimate prescription drugs from reaching patients. A suspect product must be separated from dispensable stock while the required investigation occurs. Unusual packaging, questionable sourcing, or inconsistent tracing information can justify investigation even when the product is unexpired. Quarantine is a protective status, not a final determination of illegitimacy. Preserve the packaging and records needed to investigate rather than returning the product to circulation.
Apply it
A received prescription-drug package has altered-looking identifiers and does not match the accompanying tracing information. Segregate it, preserve the shipment documentation, and promptly notify the pharmacist to begin the suspect-product investigation process.
Common pitfall: An intact-looking tablet does not resolve a supply-chain concern. Quarantine should not be bypassed merely because patients are waiting or replacement stock is inconvenient.
FDA: Pharmacists—Utilize DSCSA Requirements to Protect Your Patients
32.How do product-tracing records support DSCSA accountability?
Product-tracing information connects received prescription-drug stock to its supply-chain history. FDA identifies a six-year retention requirement for applicable tracing documentation. These records support investigations and should remain accessible when product integrity is questioned. A commercial invoice may contain useful purchasing information without necessarily constituting all required tracing documentation. Keep the connection between the specific received product, its transaction information, and its supplier rather than retaining an unexplained pile of invoices.
Apply it
During a suspect-product investigation, the pharmacist requests records for a shipment received several years earlier. Locate the applicable tracing documentation and associated identifiers so the shipment's history can be evaluated rather than relying on current shelf stock alone.
Common pitfall: Do not discard tracing records because the stock has been sold. A completed dispensing transaction does not end the documentation's role in a later investigation.
FDA: Pharmacists—Utilize DSCSA Requirements to Protect Your Patients
Patient Safety and Quality Assurance23.75%
33.What makes insulin a high-alert medication?
High-alert medications carry a heightened risk of significant harm when used in error. Insulin is an example. The designation concerns the consequences of mistakes, not a claim that every correctly used dose is unusually unsafe or that errors always occur more often. This distinction supports careful product, concentration, dose, and device verification. Familiarity with a medication should not reduce attention to checks that address a potentially severe error outcome.
Apply it
Two insulin products have similar packaging but different labelled concentrations. Before staging either product, compare the order with the exact product and concentration and ensure the associated supplies match the intended administration system.
Common pitfall: Do not interpret high-alert as meaning the medication should never be used. The appropriate response is targeted safeguards against consequential selection and administration errors.
ISMP Guidelines for Optimizing Safe Subcutaneous Insulin Use in Adults, 2017 · PTCE Content Outline — Effective January 6, 2026
34.How does Tall Man lettering reduce look-alike name errors?
Tall Man lettering highlights differing portions of otherwise similar drug names. It directs attention to the characters that distinguish products and helps interrupt recognition based on a familiar word shape. FDA's name-differentiation examples include buPROPion and busPIRone. The visual cue supports, rather than replaces, reading the complete medication name and checking strength and dosage form. Storage separation and barcode checks can add protection against the same selection hazard.
Apply it
Adjacent bins contain buPROPion and busPIRone. Read the full name on the order and selected container, use the highlighted differences as a cue, and follow the barcode process before the product advances.
Common pitfall: Capital letters are not a complete verification system. A correct-looking name can still be paired with the wrong strength, formulation, patient, or directions.
35.How do patient identifiers prevent wrong-patient dispensing?
A medication can be correctly prepared for one person yet become an error when assigned or released to another. Compare independent patient details, such as name and date of birth, across the order, profile, and pickup information. Similar names and shared addresses create predictable confusion. Resolve mismatches before release; a familiar face, matching surname, or bag location is weaker evidence than direct agreement between the patient and the intended record.
Apply it
Two patients named Jordan Lee have prescriptions waiting. Their dates of birth differ. Confirm the collecting patient's details and match them with the prescription record before selecting the bag, even though both prescriptions are on the same shelf.
Common pitfall: A shared surname or address can belong to several people. Do not treat a correctly labelled bag as proof that it has reached the intended patient.
36.Why should a barcode mismatch stop product selection?
Barcode verification compares the scanned product identifier with the expected product in the processing system. A mismatch can expose wrong-drug, wrong-strength, or wrong-package selection before release. Investigate the actual selected container and order rather than scanning a convenient matching label elsewhere. Barcode agreement addresses only what the system compares; it does not independently establish patient identity, prescription appropriateness, or the correctness of directions entered into the record.
Apply it
The selected bottle produces a barcode mismatch for the ordered strength. Set it aside and compare the container, prescription, and product record to identify the discrepancy before proceeding through the pharmacy's approved verification workflow.
Common pitfall: Scanning a shelf label or another bottle can falsely validate the selected product. A successful scan also cannot correct an incorrectly entered prescription.
37.Why are leading zeros protective and trailing zeros hazardous?
Write a leading zero for amounts below one, such as 0.5 mg, and omit unnecessary trailing zeros, such as writing 5 mg instead of 5.0 mg. A missed decimal can otherwise create a tenfold interpretation error. The leading zero makes the decimal position visible; removing the trailing zero removes an unnecessary digit that could be mistaken for part of a larger whole number. Always retain the unit with the value.
Apply it
An entered direction displays .5 mg in one field and 5.0 mg in another. Compare both with the original order and correct the presentation to an unambiguous value without independently changing the prescribed dose.
Common pitfall: Formatting and prescribing are different tasks. Do not resolve conflicting dose values merely by adding or removing zeros; the intended prescription must first be established.
FDA Safe Use Initiative: Current Projects · PTCE Content Outline — Effective January 6, 2026
38.When should ambiguous prescription shorthand be clarified?
Prescription shorthand is useful only when its meaning is unambiguous in context. An unclear frequency, route, decimal, or unit can change the medication's use and create a serious error. Compare the original order with the entered interpretation and identify exactly which element is unresolved. Hold the affected processing step for clarification rather than selecting the most familiar interpretation. Clear patient directions should express the confirmed meaning in understandable language.
Apply it
A handwritten frequency could reasonably be read as once daily or four times daily. Preserve the original order and identify the uncertain frequency for pharmacist clarification before calculating a final quantity or printing patient instructions.
Common pitfall: A familiar abbreviation pattern does not justify guessing from unclear handwriting. A quantity that fits one interpretation does not prove that the prescriber intended it.
39.Which medication questions require pharmacist clinical judgement?
Drug interactions, therapeutic substitution, adverse effects, adherence concerns, and OTC recommendations can require patient-specific clinical judgement. The technician can identify the issue and gather concrete information, including actual medication use, symptoms, timing, and relevant products. That preparation makes pharmacist intervention more effective. The key distinction is between accurate processing of an established order and deciding whether a medicine or treatment change is clinically appropriate for a particular patient.
Apply it
A patient requests an OTC product while reporting several prescription medicines and a new symptom. Record the products, symptom onset, and intended use, then connect the patient with the pharmacist before a recommendation is made.
Common pitfall: Reciting a product's labelled use does not answer whether it is appropriate for this patient. Avoid substituting a personal recommendation for the pharmacist's assessment.
40.How should an incomplete allergy entry be investigated?
An allergy entry without a reaction description leaves important uncertainty. Gather the implicated medication, what happened, approximate timing, and whether urgent treatment was required. Document the patient's report accurately so the pharmacist can distinguish an adverse effect, uncertain historical label, or potentially serious hypersensitivity. Do not erase an entry merely because details are missing, and do not convert an unexplained symptom into a confirmed severe allergy without supporting information.
Apply it
A profile says penicillin allergy, but no reaction is recorded. Ask the patient to describe the event and communicate the account to the pharmacist before a related antibacterial prescription is assessed for dispensing.
Common pitfall: An incomplete entry is neither proof of a harmless reaction nor proof of anaphylaxis. Removing uncertainty requires better information and appropriate clinical assessment.
PTCE Content Outline — Effective January 6, 2026 · DailyMed: Amoxicillin powder for oral suspension
41.How do wrong-dose and wrong-quantity errors differ?
A wrong-dose error changes the amount intended for each administration, while a wrong-quantity error changes the total amount supplied. The two can occur independently: directions may be correct while the bottle contains too few tablets, or the quantity may appear reasonable despite incorrect directions. Compare the original prescription with the label and physical supply separately. Classifying the discrepancy precisely helps identify the failed step and prevents a superficial correction.
Apply it
An order requires one tablet twice daily for ten days, but the bottle contains ten tablets with otherwise correct directions. Identify a quantity discrepancy: the intended regimen requires twenty tablets, subject to verification against the complete order.
Common pitfall: Do not change correct directions to make an incorrect quantity appear consistent. Agreement between two erroneous fields does not establish agreement with the prescription.
42.Why should a near miss be reported even without injury?
A near miss involves an error or hazardous situation that causes no injury because it is detected or because harm is avoided by chance. The absence of injury does not make the underlying process reliable. Reporting preserves information about the failure, the point of detection, and the protection that worked. Distinguish this from an adverse event, which involves harm associated with care; an error can occur without producing an adverse event.
Apply it
A wrong-strength bottle is selected, but the final check detects it before release. Correct the selection and document the event through the near-miss process so the storage or selection hazard can be assessed.
Common pitfall: A successful final check does not erase the earlier error. Suppressing intercepted events removes opportunities to identify risks before a similar error causes harm.
43.How do MedWatch and VAERS serve different reporting needs?
FDA MedWatch provides reporting pathways for adverse events and product problems involving covered medical products. Vaccine adverse events have the separate Vaccine Adverse Event Reporting System, VAERS. Match the report to the relevant product and event rather than using one destination for every safety concern. Preserve product identifiers, event timing, and the patient's description. Reporting a suspected association does not establish causation, and submitting a report does not replace immediate patient assessment.
Apply it
A patient reports a concerning event after vaccination, while another reports a suspected reaction to a prescription tablet. Help the pharmacist gather details and use the appropriate vaccine or non-vaccine reporting pathway for each event.
Common pitfall: Do not wait for certainty that the product caused the event before recognising a reportable concern. Reporting systems also do not provide emergency treatment.
44.How does root cause analysis lead to stronger corrective action?
Root cause analysis examines how system conditions and human actions combined to permit an event. Useful analysis reconstructs the process, identifies contributing factors, and links those factors to corrective action. Merely naming the last person involved rarely explains why the system allowed the error. Stronger changes address the demonstrated failure mechanism, and follow-up measurement checks whether the intervention was implemented and reduced the targeted risk over time.
Apply it
Repeated selection errors involve two similar packages stored together. Review the workflow and detection points, then evaluate storage separation and verification changes while tracking whether the same selection errors continue after implementation.
Common pitfall: A reminder to be careful may leave the original hazard intact. A corrective action is incomplete without an owner, implementation, and evaluation of its effect.
45.Why is hand hygiene needed before and after glove use?
Gloves do not replace hand hygiene. CDC directs hand hygiene before donning gloves for tasks requiring them and cleaning hands after glove removal. Hands can contaminate gloves during application, and contamination can occur during use or removal. The protective sequence therefore includes both hand hygiene and appropriate glove handling. Change gloves when the task or contamination requires it rather than treating one pair as a barrier for an entire work session.
Apply it
After a patient-care task, a technician removes gloves and reaches for clean supplies. Perform hand hygiene before handling the clean items, and use fresh gloves when the next task requires them rather than reusing the previous pair.
Common pitfall: Clean-looking gloves can still transfer contamination. Wearing the same pair across dirty and clean tasks undermines the barrier and does not eliminate hand-hygiene requirements.
46.What makes equipment cleaning and disinfectant application adequate before reuse?
Cleaning removes medication residue and other soil; disinfection inactivates microorganisms and does not substitute for residue removal. First remove residue using a method compatible with the equipment. When the infection-prevention schedule or contamination circumstances require disinfection, apply the appropriate disinfectant according to its label, including concentration, application method, and the full specified contact time. Keep the treated surface wet for the required contact period when the label specifies wet contact. Complete any required rinsing and drying before medication touches the surface. Equipment instructions must also permit the treatment. These operational criteria follow the label-based approach described in [CDC guidance](https://www.cdc.gov/infection-control/hcp/disinfection-sterilization/healthcare-equipment.html); there is no universal disinfectant or contact time for every pharmacy surface.
Apply it
Consider a hypothetical counting-tray procedure: the tray manufacturer permits detergent cleaning and the selected disinfectant, and routine scheduling calls for both cleaning and disinfection. For this example, the disinfectant instructions specify use undiluted, wipe application, two minutes of continuous wet contact, a potable-water rinse on medication-contact surfaces, and air drying. Remove the non-hazardous powder with the compatible detergent method and complete its rinsing instructions. Then apply the disinfectant undiluted, keep the surface wet for the full two minutes, rinse as specified, and let it air dry completely before counting another medication. The example's two-minute interval applies only to its stated instructions.
Common pitfall: A quick wipe that dries before the required contact time does not complete the stated disinfection process. Conversely, disinfecting visible powder without first removing it does not adequately address medication carryover. Routine cleaning and disinfection also do not establish that hazardous drug residue has been safely removed; use the separate substance-specific hazardous-residue procedure and required protective measures.
Order Entry and Processing22.50%
47.How does dimensional analysis prevent unit-conversion errors?
Dimensional analysis arranges conversion factors so unwanted units cancel and the required unit remains. Start with the known amount, write the target unit, and choose equivalent quantities that connect them. For metric mass, 1 gram equals 1,000 milligrams and 1 milligram equals 1,000 micrograms. Keep units visible throughout the work, then assess whether the magnitude is reasonable. A correct numerical operation with the wrong unit can still produce a dangerous answer.
Apply it
A processing exercise asks for the milligram equivalent of 0.25 g. Multiply by 1,000 mg per gram to obtain 250 mg, then verify that the smaller unit appropriately produces a larger numerical value.
Common pitfall: Do not move a decimal by memory without checking the direction. Confusing milligrams and micrograms creates a thousandfold error despite similar-looking abbreviations.
48.How is a prescribed liquid dose converted into millilitres?
Divide the prescribed drug amount by the product concentration expressed in matching units. A suspension labelled 250 mg per 5 mL contains 50 mg per mL, so a prescribed 375 mg amount corresponds to 7.5 mL. The calculation depends on selecting the actual dispensed concentration. Write the complete proportion or unit-cancelling equation and verify the resulting volume against the prescription before preparing directions and selecting a measuring device.
Apply it
For an arithmetic-only exercise, a verified order requires 375 mg per dose and the selected suspension contains 250 mg/5 mL. Calculate 375 × 5 ÷ 250 = 7.5 mL per dose before preparing the label.
Common pitfall: The 5 mL denominator is part of the concentration. Treating 250 mg/5 mL as 250 mg/mL produces a fivefold volume error.
PTCE Content Outline — Effective January 6, 2026 · DailyMed: Amoxicillin powder for oral suspension
49.How is the total quantity for a fixed course calculated?
For a constant regimen, total quantity equals the amount used per administration multiplied by administrations per day and treatment days. Keep the dosage unit consistent: millilitres produce a liquid quantity, while tablets produce a tablet count. Confirm that the order actually describes a fixed schedule before applying the formula. Tapers and changing schedules require separate calculations for each segment rather than multiplying one day's use across the entire course.
Apply it
A verified order specifies 7.5 mL twice daily for seven days. Calculate 7.5 × 2 × 7 = 105 mL for the prescribed course, then compare this requirement with the ordered quantity and available package sizes.
Common pitfall: Do not round the calculated treatment requirement down to fit a convenient bottle. Package selection and the arithmetic quantity are related but separate processing decisions.
50.How is days supply calculated for a fixed tablet regimen?
Days supply equals total usable quantity divided by the number of dosage units used each day. Determine daily use from both the number taken at a time and the administration frequency. For example, one and one-half tablets twice daily uses three tablets per day. This processing calculation describes how long the supplied quantity lasts under the stated directions; it does not establish whether the prescribed regimen is clinically appropriate.
Apply it
A prescription supplies 90 tablets with verified directions to take one and one-half tablets twice daily. Daily use is three tablets, so 90 ÷ 3 gives a 30-day supply under the stated regimen.
Common pitfall: Counting only the twice-daily frequency ignores tablets per administration. Do not round intermediate daily use before calculating the final supply duration from the verified directions.
51.How should an explicit maximum guide an as-needed days-supply exercise?
An as-needed regimen does not guarantee a fixed actual daily use. When an exercise explicitly directs calculation at the prescribed maximum, derive the maximum daily quantity from the complete directions and divide the supplied quantity by that amount. State the assumption. If the order lacks a necessary maximum or contains conflicting limits, clarify rather than inventing one. Actual patient use and payer-specific processing requirements may differ from a simplified arithmetic exercise.
Apply it
An exercise specifies 24 tablets, one tablet every six hours as needed, maximum four daily, and asks for supply at maximum use. Divide 24 by four to obtain six days under that explicit assumption.
Common pitfall: Do not present maximum-use arithmetic as a prediction of actual consumption. An unrestricted guess about patient use cannot supply a missing prescribed limit.
52.How does conservation of drug amount guide a dilution calculation?
In a simple dilution, adding compatible diluent changes concentration and volume without changing the amount of drug contributed by the stock solution. When units and concentration expressions match, C1V1 = C2V2 relates stock concentration and volume to the final preparation. The calculated final volume includes the stock solution. In a stated additive-volume exercise, subtract the stock volume from the final volume to determine diluent, rather than adding the entire final volume again.
Apply it
A calculation-only exercise uses a compatible 20 mg/mL stock to prepare 100 mL at 5 mg/mL, assuming additive volumes. Use 25 mL stock and enough diluent to reach 100 mL, equivalent to 75 mL diluent under that assumption.
Common pitfall: Adding 100 mL diluent to 25 mL stock yields 125 mL and the wrong concentration. Clinical compatibility is not established by a correct equation.
53.What does a stated percentage concentration mean?
A percentage concentration must be interpreted with its basis. A 1% weight-in-volume solution contains 1 gram per 100 mL, equivalent to 10 mg/mL. Weight-in-weight and volume-in-volume percentages describe different relationships, so the percent symbol alone is incomplete for calculation. Convert the stated basis into useful units before multiplying by volume or mass. This prevents treating a concentration expression as though it were an absolute amount of drug.
Apply it
An arithmetic exercise specifies a 2% weight-in-volume solution and asks how much drug is in 15 mL. Convert to 20 mg/mL, then calculate 15 × 20 = 300 mg in that stated volume.
Common pitfall: Two percent weight-in-volume is not 2 mg/mL. Do not use a percentage calculation until the weight or volume basis has been established.
54.How should recognised Sig codes become clear patient directions?
Recognised Sig codes compress prescription information, but patient directions should communicate the confirmed meaning clearly. For example, b.i.d. means twice daily and t.i.d. means three times daily; Roman numeral ii represents two. Interpret each component in context, including units, route, and duration. A frequency abbreviation does not by itself specify the quantity taken each time. Preserve the intended regimen while replacing unfamiliar shorthand with understandable language.
Apply it
A clearly written exercise states one tablet by mouth b.i.d. for ten days. Translate the directions as one tablet by mouth twice daily for ten days, then calculate twenty tablets for that fixed course.
Common pitfall: Do not translate twice daily into an invented exact interval when none is specified. Recognising one code does not resolve another unclear component of the order.
55.Which device best supports an accurately measured oral liquid dose?
Choose a calibrated oral dosing device whose units and graduations support the prescribed volume. Small or fractional volumes often require an oral syringe rather than a household spoon or broadly graduated cup. Match the label's units to the device so the patient does not need an unnecessary conversion. The device should support oral administration and practical measurement; merely having enough total capacity does not establish that its markings are suitable.
Apply it
A verified liquid dose is 2.5 mL. Select a calibrated oral syringe with a clear 2.5 mL measurement and appropriate capacity, then ensure the printed directions use millilitres consistently with the supplied device.
Common pitfall: A household teaspoon is not a calibrated dosing device. A large cup with coarse markings may hold the dose yet fail to measure it reliably.
FDA Safe Use Initiative: Current Projects · PTCE Content Outline — Effective January 6, 2026
56.Why must insulin supplies match the product and concentration?
Insulin products and delivery supplies must be matched to the intended administration system and labelled concentration. A syringe's unit scale is meaningful only in relation to the insulin concentration for which it is designed. Pens and vials also require different associated supplies. Verify the prescribed product, presentation, and equipment together rather than treating all insulin supplies as interchangeable. This is a product-and-device selection principle, not a method for independently converting a patient's regimen.
Apply it
An order requests insulin in a pen presentation, but the prepared supplies are intended for vial withdrawal. Reconcile the presentation and required supplies with the prescription before staging the order for pharmacist verification.
Common pitfall: Equal-looking volume markings do not guarantee equal insulin amounts across concentrations. Do not improvise a conversion or substitute a delivery system without appropriate authorisation.
PTCE Content Outline — Effective January 6, 2026 · ISMP Guidelines for Optimizing Safe Subcutaneous Insulin Use in Adults, 2017
57.How are inhaler spacers and nebulizer supplies selected?
Administration supplies must match the ordered dosage form and delivery system. A spacer is associated with compatible metered-dose inhaler use, while nebulizer medication requires an appropriate nebulizer setup. A shared medication name does not make these systems interchangeable. Read the complete order and product presentation before selecting accessories. If the prescription and equipment request conflict, identify the mismatch so the intended route and device can be confirmed before dispensing.
Apply it
A prescription specifies albuterol inhalation aerosol with a compatible spacer, but a nebulizer cup is selected as the accessory. Compare the requested delivery system with the supplies and correct the mismatch through the verification process.
Common pitfall: The word inhalation does not identify one universal device. Do not substitute nebulizer solution for aerosol merely because both deliver the same named medication to the lungs.
PTCE Content Outline — Effective January 6, 2026 · DailyMed: Albuterol sulfate inhalation aerosol
58.What does an NDC identify during product selection?
The National Drug Code identifies a drug product and package through its labeler, product, and package components. It serves a different purpose from a lot number or expiration date. Compare the actual product record and packaging rather than relying on a memorised total digit count, because NDC formatting has distinct uses and transition requirements. Matching identifiers supports selection, but the order's drug, strength, dosage form, and package still require careful agreement.
Apply it
Two containers share the same ingredient and strength but differ in package presentation. Compare their product records and NDC information to select the ordered presentation, then separately inspect the selected container's lot and expiration.
Common pitfall: An NDC is not a unique manufacturing-batch identifier. A matching NDC does not prove that a container is unexpired, unrecalled, or otherwise suitable for dispensing.
FDA: National Drug Code Format · PTCE Content Outline — Effective January 6, 2026
59.How do lot numbers and expiration dates answer different inventory questions?
A lot number links product to a manufacturing batch and supports targeted investigation or recall. An expiration date marks the labelled shelf-life limit under specified conditions. Neither substitutes for the other: the correct lot can be expired, and an unexpired lot can be recalled. For products with a shorter period after reconstitution or opening, consider that additional limit too. Determine eligibility for use from all applicable identifiers and handling information.
Apply it
A recall notice identifies lot K27. One shelf container is lot K27 and unexpired; another is a different lot but expired. Segregate each for its respective problem rather than treating either as automatically dispensable.
Common pitfall: An unexpired date cannot clear a recalled lot. The manufacturer's unopened expiration also cannot override a shorter product-specific period after preparation or opening.
PTCE Content Outline — Effective January 6, 2026 · FDA: Recalls Background and Definitions · FDA: Don't Be Tempted to Use Expired Medicines
60.When is returned inventory suitable for stock, credit, or another disposition?
Disposition depends on product integrity, expiration, custody, recall status, and applicable return procedures. An uncollected prescription kept under pharmacy control presents different questions from a product returned after patient possession. Separate potentially dispensable stock from expired or otherwise non-dispensable material before evaluating return-to-stock, supplier credit, or reverse-distribution pathways. Financial credit and suitability for patient use are independent decisions; a product can qualify for a return process while remaining unsuitable for dispensing.
Apply it
An uncollected prescription remains in controlled pharmacy storage, while a patient also brings back an opened bottle from home. Evaluate the two through their appropriate procedures instead of merging both into usable stock because the labels match.
Common pitfall: Do not assume that an unexpired patient-returned bottle is eligible for re-dispensing. A supplier's willingness to issue credit does not establish product suitability for use.
PTCE Content Outline — Effective January 6, 2026 · FDA: Don't Be Tempted to Use Expired Medicines
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Build medication links in both directions: brand to generic, ingredient to class, class to major risk, and dosage form to administration requirement.
- Practise discriminating boundaries: duplicate therapy versus a replacement order, allergy versus adverse effect, and contraindication versus precaution.
- Keep Schedule II refill prohibition separate from the Schedule III–IV limits, partial dispensing, stock ordering, and prescription transfers.
- Connect each safety cue to a concrete action: resolve identifier mismatches, investigate barcode alerts, quarantine suspect products, and report intercepted errors.
- Calculate with visible units and explicit assumptions, then independently compare dose, directions, quantity, concentration, and days supply.
- Use product-specific labels for storage, reconstitution, preparation, and discard periods instead of applying one product's instructions to an entire class.
A practical preparation plan
1. Map the complete outline
Read the official 2026-effective outline and mark each knowledge area as secure, developing, or unfamiliar. Use the four published weights to distribute study time while preserving coverage of every domain.
2. Create medication comparison pairs
Study medicines through contrasts that change a decision: nitrate versus alpha-blocker interaction, extended-release versus alterable formulation, and original expiration versus post-reconstitution discard period. Explain the distinguishing cue aloud.
3. Separate legal transaction types
For each federal scenario, first identify the substance category and transaction: new prescription, refill, partial dispensing, stock acquisition, recall, collection, or disposal. Then apply the rule supported for that transaction.
4. Work calculations from the order
Write the supplied values and requested unit before calculating. Complete dose-volume, course-quantity, days-supply, percentage, and dilution exercises, then check whether the result matches the stated assumptions and physical product.
5. Review the mechanism behind every error
After each question, explain the decisive cue and why each alternative fails. Record whether your mistake involved knowledge, reading, units, product selection, or confusing two legal or clinical categories.
6. Retest across domains
Mix recall cards with short application cases and revisit missed material after a delay. Return to the full official outline regularly so this selective guide does not become your only measure of coverage.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- PTCB Certified Pharmacy Technician (CPhT)
- PTCE Content Outline — Effective January 6, 2026
- 2026 PTCB Certified Pharmacy Technician Knowledge Reference
- DailyMed: Lipitor prescribing information
- DailyMed: Naproxen tablets prescribing information
- DailyMed: Sildenafil citrate tablets prescribing information
- DailyMed: Albuterol sulfate inhalation aerosol
- DailyMed: Metformin hydrochloride extended-release tablets
- DailyMed: Levothyroxine sodium tablets
- DailyMed: Amoxicillin powder for oral suspension
- DEA Pharmacist's Manual, 2022 Edition
- FDA: Combat Methamphetamine Epidemic Act
- FDA: Pharmacists—Utilize DSCSA Requirements to Protect Your Patients
- FDA Safe Use Initiative: Current Projects
- FDA Name Differentiation Project
- AHRQ PSNet: Adverse Events, Near Misses, and Errors
- CDC: Clinical Safety—Hand Hygiene for Healthcare Workers
- FDA: National Drug Code Format
- FDA: What's in a REMS?
- FDA: Recalls Background and Definitions
- FDA: MedWatch Forms for FDA Safety Reporting
- AHRQ PSNet: Root Cause Analysis
- FDA: Don't Be Tempted to Use Expired Medicines
- ISMP Guidelines for Optimizing Safe Subcutaneous Insulin Use in Adults, 2017
- Federal Register :: Request Access
- Federal Register :: Request Access
- Federal Register :: Request Access
- 2023-13085.pdf
- Diversion Control Division | Controlled Substance Schedules
- Frequent Questions about the Management Standards for Hazardous Waste Pharmaceuticals and Amendment to the P075 Listing for Nicotine Final Rule | US EPA
- Diversion Control Division | CMEA General Information
- %28DEA-DC-054%29%28EO-DEA168%29_Chemical_Handler%27s_Manual_Final_%28OMB_Approved%29.pdf
- Pseudoephedrine Hydrochloride 30 mg Drug Facts
- National Drug Code Database Background Information | FDA
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.